Skip to main content
. 2022 Feb 20;23(4):2333. doi: 10.3390/ijms23042333

Figure 3.

Figure 3

CRISPR-Cas9 knockout of CD133 expression in parental BAKP melanoma cells (A) increases caspase-3 mediated apoptosis (B,C) after exposure to trametinib. (A) Immunoblot analysis with anti-CD133 in BAKP-SC vs. BAKP-KO cells (left panel) and POT SC vs. POT-KO cells (right panel). (B) BAKP-SC and BAKP-KO cells were treated with indicated concentrations of trametinib (upper panels) or dabrafenib (lower panels) and subjected to Annexin FITC/PI apoptosis assays. Trametinib-treated CD133-depleted BAKP-KO cells display enhanced apoptosis relative to control BAKP-SC cells, an effect that was not seen with dabrafenib. (C) Fluorometric caspase-3 activity assays were performed 72 h after exposure of BAKP-SC and BAKP-KO cells to 100 nM trametinib. Results shown are the means ± SD of three biological replicates of a representative experiment; essentially the same results were obtained in three independent experiments. ** represents p < 0.01.